Polyclonal Antibody to EGF Like Domain Protein, Multiple 7 (EGFL7)
| Code | Size | Price |
|---|
| PAL643Hu01-20ul | 20ul | £93.00 |
Quantity:
| PAL643Hu01-100ul | 100ul | £175.00 |
Quantity:
| PAL643Hu01-200ul | 200ul | £237.00 |
Quantity:
| PAL643Hu01-1ml | 1ml | £547.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ZNEU1; MEGF7; Zneu1; Vascular endothelial statin; EGF Like Domain Containing 7; Epidermal growth factor-like protein 7; Multiple epidermal growth factor-like domains protein 7
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
EGF Like Domain Protein, Multiple 7
Reactivity:
Mu;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blottin:g: 0.5-5ug/mL;<br/>Immunohistochemistry: 5-50ug/mL;<br/>Immunocytochemistry: 5-50ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant EGF Like Domain Protein, Multiple 7 (EGFL7) | RPL643Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||